Research programme: mast cell stabilisers - Bridge PharmaAlternative Names: Mast cell stabilisers research programme - Bridge Pharma
Latest Information Update: 28 May 2007
At a glance
- Originator Bridge Pharma
- Mechanism of Action Mast cell stabilisers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 17 Jun 2002 Bridge Pharma and Immune Network have terminated their joint venture
- 26 Apr 2000 Preclinical development for Asthma in USA (PO)